Drug intelligence / Profile preview

RC-01

Development stage: Phase 1
Lead developer: Recida Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

RC-01 is a small molecule drug and a first-in-class bactericidal agent. It acts as a potent inhibitor of the bacterial enzyme LpxC, which is involved in the synthesis of the bacterial outer membrane. RC-01 is being developed for the treatment of serious antibiotic-resistant infections, particularly against gram-negative bacteria such as *Enterobacteriaceae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. It was initially developed by FUJIFILM Toyama Chemical Co., Ltd. and is currently in Phase 1 clinical trials.

Targets

LpxC (UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine Deacetylase)

Beyond the preview

Go deeper on RC-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC-01.

Explore the full profile